TABLE 6.
Univariate logistic regression analysis of factors affecting the probability of nephrotoxicity caused by arbekacin treatment (n = 333)
| Variablea | Coefficient | SE | P value | Odds ratio
|
|
|---|---|---|---|---|---|
| Estimate | 95% CIb | ||||
| WT | 0.007 | 0.020 | 0.73 | 1.01 | 0.97-1.05 |
| Age | 0.044 | 0.021 | 0.038 | 1.05 | 1.00-1.09 |
| Sex | −0.360 | 0.596 | 0.55 | 0.70 | 0.22-2.24 |
| CLCR | −0.013 | 0.007 | 0.045 | 0.99 | 0.97-1.00 |
| Pneumonia | 0.360 | 0.596 | 0.55 | 1.43 | 0.45-4.61 |
| Sepsis | −0.307 | 0.774 | 0.69 | 0.74 | 0.16-3.35 |
| Antifungal | 0.578 | 0.668 | 0.39 | 1.78 | 0.48-6.60 |
| Combination therapy | 0.407 | 0.596 | 0.49 | 1.50 | 0.47-4.83 |
| Total dose | −0.001 | 0.000 | 0.07 | 1.00 | 1.00-1.00 |
| Cmaxc | 1.082 | 0.750 | 0.15 | 2.95 | 0.68-12.83 |
| Cminc | 1.098 | 0.365 | 0.0026 | 3.00 | 1.47-6.13 |
| AUC0-24c | 1.653 | 0.494 | 0.0008 | 5.22 | 1.98-13.75 |
| AUCcumc | 0.265 | 0.367 | 0.47 | 1.30 | 0.64-2.68 |
| First-Cmaxc | −0.327 | 0.578 | 0.57 | 0.72 | 0.23-2.24 |
a
Abbreviations: Combination therapy, patients with antibiotic combination therapy; Total dose, the sum of the doses of arbekacin during the treatment period; Cmin, trough concentration immediately before the last administration during treatment, but when nephrotoxicity was observed, the Cmin indicated the trough concentration immediately before the day toxicity appeared. Other abbreviations are described in footnotes a of Tables 2 and 3.
b
95% CI, 95% confidence interval.
c
These values were transformed (natural logarithmic transformation).